Comparison of Outcomes After Single or Double Cord Blood Transplantation in Adults with Acute Leukemia Using Different Types of Myeloablative Conditioning Regimen, a Retrospective Study on Behalf of Eurocord and the Acute Leukemia Working Party Of...

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2013 Sep 6

PMID 24005245

Citations 39

Authors

A Ruggeri

G Sanz

H Bittencourt

J Sanz

A Rambaldi

F Volt

I Yakoub-Agha

J M Ribera

L Mannone

J Sierra

M Mohty

C Solano

S Nabhan

W Arcese

E Gluckman

M Labopin

V Rocha

Affiliations

Soon will be listed here.

Abstract

We report outcomes after single (s) and double (d) umbilical cord blood transplantation (UCBT) after myeloablative conditioning (MAC) regimen for 239 patients transplanted for acute leukemia in first complete remission (CR1). All sUCBT patients received a total nucleated cell dose >2.5 × 10(7)/kg. Conditioning regimen for sUCBT was total body irradiation (TBI)12 Gy- or busulfan (BU)-based ± fludarabine (Flu) (n=68, group 1), thiotepa+BU+Flu (TBF) (n=88, group 2), and for dUCBT it was TBI12 Gy+cyclophosphamide ± Flu (n=83, group 3). dUCBT recipients were younger, received higher cell dose and less frequently antithymocyte globulin. In multivariate analysis, we found similar neutrophil recovery among the three groups; however, acute graft-versus-host disease II-IV was higher in dUCBT compared with others. Non-relapse mortality and relapse incidence were not statistically different among the three groups. Leukemia-free survival was 30% for sUCBT using TBI- or BU-based MAC compared with 48% for sUCBT TBF and 48% for dUCBT (P=0.02 and P=0.03, respectively), and it was not statistically different between sUCBT with TBF and dUCBT. In conclusion, use of sUCBT with adequate cell dose (>2.5 × 10(7)/kg) and a specific conditioning regimen in the MAC setting results in similar outcomes as dUCBT. The choice of TBF conditioning regimen for sUCBT may improve results, and whether this regimen may be effective in dUCBT should be further analyzed.

Citing Articles

Myeloablative conditioning in cord blood transplantation for acute myeloid leukemia patients is efficacious only until age 55.

Oshima S, Arai Y, Kondo T, Yano S, Hirabayashi S, Uchida N Bone Marrow Transplant. 2025; .

PMID: 39838078 DOI: 10.1038/s41409-025-02508-2.

Impact of allele-level HLA matching on outcomes after double cord blood transplantation in adults with malignancies.

Fatobene G, Mariano L, Volt F, Moreira F, Conelissen J, Furst S Blood Adv. 2023; 7(13):3297-3306.

PMID: 36877784 PMC: 10336258. DOI: 10.1182/bloodadvances.2022009251.

Incidence and risk factors for graft failure in the modern era of cord blood transplantation.

Holter Chakrabarty J, Glover J, Schmidt S, Phan M, Bycko M, Duong Q Vox Sang. 2022; 117(12):1405-1410.

PMID: 36250288 PMC: 9772075. DOI: 10.1111/vox.13368.

Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?.

Abou-Ismail M, Fraser R, Allbee-Johnson M, Metheny 3rd L, Ravi G, Ahn K Br J Haematol. 2022; 197(3):326-338.

PMID: 35286719 PMC: 9675037. DOI: 10.1111/bjh.18108.

Cord-Blood Engraftment Using an Enhanced Dual-Conditioning Regimen for Malignant Hematologic Diseases.

Ding J, Fang Y, Zhou R, Gu Y, Du S, Lu Q Cell Transplant. 2022; 31:9636897211070238.

PMID: 35073786 PMC: 8793423. DOI: 10.1177/09636897211070238.

References

Sanz G, Saavedra S, Planelles D, Senent L, Cervera J, Barragan E . Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. Blood. 2001; 98(8):2332-8. DOI: 10.1182/blood.v98.8.2332. View

Lee S, Chung N, Cho B, Eom K, Kim Y, Kim H . Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia. Leukemia. 2010; 24(12):2110-9. DOI: 10.1038/leu.2010.217. View

Lee J, Joo Y, Kim H, Ryoo H, Kim M, Lee G . Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol. 2012; 31(6):701-9. DOI: 10.1200/JCO.2011.40.2362. View

Costa V, McGregor M, Laneuville P, Brophy J . The cost-effectiveness of stem cell transplantations from unrelated donors in adult patients with acute leukemia. Value Health. 2007; 10(4):247-55. DOI: 10.1111/j.1524-4733.2007.00180.x. View

Laughlin M, Eapen M, Rubinstein P, Wagner J, Zhang M, Champlin R . Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004; 351(22):2265-75. DOI: 10.1056/NEJMoa041276. View

Sanz J, Boluda J, Martin C, Gonzalez M, Ferra C, Serrano D . Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant. 2012; 47(10):1287-93. DOI: 10.1038/bmt.2012.13. View

Scaradavou A, Brunstein C, Eapen M, Le-Rademacher J, Barker J, Chao N . Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood. 2012; 121(5):752-8. PMC: 3563363. DOI: 10.1182/blood-2012-08-449108. View

Verneris M, Brunstein C, Barker J, MacMillan M, DeFor T, McKenna D . Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood. 2009; 114(19):4293-9. PMC: 2774557. DOI: 10.1182/blood-2009-05-220525. View

Walter R, Pagel J, Gooley T, Petersdorf E, Sorror M, Woolfrey A . Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia. 2010; 24(7):1276-82. PMC: 3001162. DOI: 10.1038/leu.2010.102. View

10.

Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio A . Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998; 339(22):1565-77. DOI: 10.1056/NEJM199811263392201. View

11.

Avery S, Shi W, Lubin M, Gonzales A, Heller G, Castro-Malaspina H . Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood. 2010; 117(12):3277-85. PMC: 3069669. DOI: 10.1182/blood-2010-08-300491. View

12.

Dohner H, Estey E, Amadori S, Appelbaum F, Buchner T, Burnett A . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2009; 115(3):453-74. DOI: 10.1182/blood-2009-07-235358. View

13.

Barker J, Weisdorf D, DeFor T, Blazar B, McGlave P, Miller J . Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2004; 105(3):1343-7. DOI: 10.1182/blood-2004-07-2717. View

14.

Terwey T, Vega-Ruiz A, Hemmati P, Martus P, Dietz E, le Coutre P . NIH-defined graft-versus-host disease after reduced intensity or myeloablative conditioning in patients with acute myeloid leukemia. Leukemia. 2011; 26(3):536-42. DOI: 10.1038/leu.2011.230. View

15.

Rocha V, Broxmeyer H . New approaches for improving engraftment after cord blood transplantation. Biol Blood Marrow Transplant. 2009; 16(1 Suppl):S126-32. DOI: 10.1016/j.bbmt.2009.11.001. View

16.

Oran B, Wagner J, DeFor T, Weisdorf D, Brunstein C . Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2011; 17(9):1327-34. PMC: 4130206. DOI: 10.1016/j.bbmt.2011.01.007. View

17.

Kanda J, Ichinohe T, Kato S, Uchida N, Terakura S, Fukuda T . Unrelated cord blood transplantation vs related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction. Leukemia. 2012; 27(2):286-94. DOI: 10.1038/leu.2012.203. View

18.

Robin M, Sanz G, Ionescu I, Rio B, Sirvent A, Renaud M . Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT. Leukemia. 2010; 25(1):75-81. DOI: 10.1038/leu.2010.219. View

19.

Rowe J . Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol. 2010; 150(4):389-405. DOI: 10.1111/j.1365-2141.2010.08246.x. View

20.

Brunstein C, Fuchs E, Carter S, Karanes C, Costa L, Wu J . Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011; 118(2):282-8. PMC: 3138683. DOI: 10.1182/blood-2011-03-344853. View